好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Ibudilast - Phosphodiesterase Type 4 Inhibitor - Bi-Modal Therapy with Riluzole in Early [ Not Requiring Non-Invasive Ventilation ( NIV ) ] Cohort ( EC ) and Advanced [ Requiring NIV ] ( ANC ) Amyotrophic Lateral Sclerosis ( ALS ) Patients - Single-Center Adaptive Design Six-Month Double-Blind ( DB ) - Placebo-Controlled Phase 1b/2a Epoch Followed by Six-Month Open Label Extension ( OLE ) Epoch, Washout ( WO ) and Post-Washout Epoch ( PWO ) - Final Report and Future Directions
Neuromuscular and Clinical Neurophysiology (EMG)
P6 - (-)
465
Authors/Disclosures
Benjamin R. Brooks, MD, FAAN (Clinical Trials Planning LLC)
PRESENTER 		Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with 好色先生 that is relevant to AAN interests or activities.
Elena Bravver, MD No disclosure on file
Mohammed S. Sanjak, PhD (Carolinas Healthcare System) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Amber L. Ward (Carolinas Neuromuscular ALS/MDA Center) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Joanna Dojillo, MSc (MediciNova, Inc.) No disclosure on file
Kazuko Matsuda, MD (Medcinova) No disclosure on file
Yuichi Iwaki No disclosure on file
Donna C. Graves, MD, FAAN (Atrium Health) Dr. Graves has nothing to disclose.